-
Mashup Score: 1
In an interview with Targeted Oncology, Courtney Van Houzen, PharmD, shared her experience in bringing bispecific antibody treatments to a community setting.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 14Overview of the ADRIATIC Study - 3 day(s) ago
Panelists provide an overview of the ADRIATIC study, highlighting its objectives, design, and significant results in the context of chronic spontaneous urticaria management.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2
Antonious Hazim, MD, shares insights on his journey into oncology, his experiences at the Mayo Clinic, and his ongoing research.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
In an interview with Targeted Oncology, Courtney Van Houzen, PharmD, shared her experience in bringing bispecific antibody treatments to a community setting.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
Carl He, MD, explores the barriers to adherence to treatment recommendations offered by the multidisciplinary team meeting in cancer care.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
A clinical trial evaluated the ability of oxygen-enhanced MRI-derived hypoxic volume to detect radiotherapy-induced hypoxia modification.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 5
Pirtobrutinib was safe and demonstrated activity in patients with Richter transformation, according to a subgroup analysis of the BRUIN trial.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 5
Pirtobrutinib was safe and demonstrated activity in patients with Richter transformation, according to a subgroup analysis of the BRUIN trial.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 4
Evorpacept plus TRP generated clinically meaningful, robust, and durable responses in patients with previously treated HER2-positive gastric or GEJ cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 5
Pirtobrutinib was safe and demonstrated activity in patients with Richter transformation, according to a subgroup analysis of the BRUIN trial.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
Courtney Van Houzen, PharmD, shared her experience in bringing bispecific antibody treatments to a community setting. #MedTwitter #oncology https://t.co/95y6pFCwgR https://t.co/PGElySFyCd